BIOX — Bioceres Crop Solutions Corp.

Summary of Bioceres Crop Solutions Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenues: $77.5 million, a 17% decline year-over-year.
• Gross Profit: $36.2 million, a slight decrease of 3% year-over-year, with gross margin expanding to 47% from 40%.
• Adjusted EBITDA: $13.6 million, up 61% from $8.5 million in the same quarter last year.
• SG&A Costs: Significant reduction, achieving 50% of the targeted annualized savings of $10 million to $12 million in just one quarter.
• Financial Debt: Total financial debt decreased to $242.5 million from $260.2 million, with current debt totaling $188.7 million, including $103.6 million classified as accelerated debt.

2. Strategic Updates and Business Highlights

• The company is transitioning its seed business to a more scalable and capital-efficient model, which has resulted in a similar gross profit with lower working capital expenses.
• The focus remains on improving revenue quality, protecting margins, and maintaining operational discipline.
• Key performance indicators (KPIs) include maintaining gross margins above 40%, achieving close to 4 months of working capital, and targeting adjusted EBITDA above 20% of sales.

3. Forward Guidance and Outlook

• The company expects continued revenue declines in the Seed and Integrated Products segment for at least two more quarters due to the unwinding of the HB4 downstream program.
• Management remains optimistic about improving profitability and liquidity while navigating a complex market environment.

4. Bad News, Challenges, or Points of Concern

• Revenue declines were driven by sluggish demand in Argentina, particularly in Crop Protection, and lower sales in the Seed and Integrated Products segment.
• The company is facing challenges related to tight credit conditions and uncertainty surrounding Argentina's midterm elections.
• A dispute with holders of secured convertible and nonconvertible notes has resulted in a reclassification of debt, raising concerns about liquidity and financial flexibility.

5. Notable Q&A Insights

• There is potential for increased demand for agricultural inputs from Argentina to the U.S. following recent elections, which could benefit Bioceres.
• The company has not yet registered bioprotection products in Europe, impacting expected sales from Corteva; however, biostimulant sales are improving in Latin America.
• Management emphasized the importance of maintaining dialogue with lenders and prioritizing financial flexibility amidst ongoing challenges.

Overall, while Bioceres has made strides in improving margins and reducing costs, it faces significant headwinds in revenue generation, particularly in key markets like Argentina. The company is focused on strategic transitions and maintaining operational discipline to navigate these challenges.